Biogen Inc. (BIIB) Stock
NASDAQBIIB has an Alpha Score of 47 out of 100 (weak), computed on Nov 2, 2026 from 3 of 4 sub-scores. 24 members of Congress disclosed 63 trades in BIIB since 2013: 30 purchases and 33 sales, most recently Maria Elvira Salazar (partial sale, Sep 24, 2026). 7 of the hedge funds AlphaScala tracks reported BIIB in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $90.39M. Its trailing P/E ratio is 43.9 and its net margin 8.3% (key statistics as of Oct 29, 2026).
What is BIIB's Alpha Score?
How it works →Alpha Score of 47 reflects weak overall profile with strong momentum, poor value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 2, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Biogen Inc. (BIIB)?
Most recent: Maria Elvira Salazar (partial sale, Sep 24, 2026); records start Dec 20, 2013.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Maria Elvira Salazar R-FL · House | 2026-09-24 | partial sale | $1k – $15k |
| Kevin Hern R-OK · House | 2026-08-18 | sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-06-05 | purchase | $1k – $15k |
| Maria Elvira Salazar R-FL · House | 2026-06-02 | sale | $15k – $50k |
| Maria Elvira Salazar R-FL · House | 2026-05-12 | purchase | $1k – $15k |
| Maria Elvira Salazar R-FL · House | 2026-05-11 | purchase | $1k – $15k |
| Maria Elvira Salazar R-FL · House | 2026-05-11 | purchase | $50k – $100k |
| Alan Armstrong R-OK · Senate | 2026-03-27 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded BIIB, with filing lags →Which hedge funds own BIIB?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 418K | $90.39M | +203% |
| Point72 Steve Cohen | 88K | $19.05M | -89% |
| Renaissance Technologies Jim Simons (founder) | 78K | $16.80M | -62% |
| D.E. Shaw David Shaw | 74K | $16.08M | NEW |
| Hussman Investment Trust John Hussman | 21K | $4.54M | +233% |
| Marshall Wace | 13K | $2.72M | -95% |
| Blackstone | 2K | $445.1K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Biogen Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 4, 26 | Minor Lloyd | Director | SELL | 593 | $119K |
| Aug 3, 26 | Minor Lloyd | Director | SELL | 593 | $121K |
| Feb 12, 26 | Murphy Nicole | Head of Pharm Ops and Tech | BUY | 3 | $585 |
SEC Form 4 filings as of Oct 30, 2026 · not updated for 4 days; newer filings may exist
See cluster-buy signals across all tickers →What are BIIB's key statistics?
Key statistics as of Oct 29, 2026
How does BIIB's valuation compare with the Healthcare sector?
| Metric | BIIB | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 43.9 | 27.2 | 99 |
| Net margin | 8.32% | 4.85% | 143 |
| Return on equity | 4.51% | 6.68% | 162 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 3, 2026). P/E excludes loss-making companies.
BIIB price chart
Powered by TradingViewWhat does Biogen Inc. do?
Biogen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers products such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis; SPINRAZA for spinal muscular atrophy; SKYCLARYS for Friedreich's Ataxia; QALSODY for amyotrophic lateral sclerosis; FUMADERM for plaque psoriasis; BENEPALI, an etanercept biosimilar; and IMRALDI, an adalimumab biosimilar. Biogen Inc. focuses on addressing unmet medical needs in the fields of neurology, including multiple sclerosis, spinal muscular atrophy, and rare diseases like Friedreich's Ataxia and ALS. Its portfolio emphasizes innovative treatments that target the underlying mechanisms of these debilitating conditions, serving patients through specialized healthcare channels worldwide. Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen Inc. plays a vital role in advancing biopharmaceutical solutions for complex neurological disorders.